Complete Genomics, Inc (GNOM)

[da_trader]

GNOM is a Buyout Target Candidate !!! This will run....


Complete Genomics Inc. (GNOM) facts:

Swiss giant corporation Roche made a hostile offer to buy Illumina Inc. for $5.7 billion. There are more drugmakers “fishing” for an acquisitions in the “DNA space” such as Danaher Corp., Thermo Fisher Scientific Inc. or Agilent Technologies Inc. Complete Genomics Inc. (GNOM) is a potential buyout target for them.

GNOM revenues are at about $21 million in 2011, and are expected to surge to about $37 million in 2012.

GNOM has about $105M cash in hands versus $23.6M in debt

GNOM has enough cash to avoid secondary offering in mid-term – dilution is not expected

GNOM traded below its book value

GNOM has free trading count below 18M shares with short interest of over 25% (quarter of the all floating shares) – short squeeze is imminent on any buyout announcement.

GNOM has enough space to run: its 52Week ranges are from $2.21 to $18.55


http://pennystockhaven.com/complete-genomics-inc-gnom-buyout-target-candidate/